Steve Gillis, Ph.D.
Dr. Steven Gillis is a managing director with ARCH Venture Partners, joining the firm in 2005. Dr. Gillis is focused on the evaluation of new life science technologies and also on the development and growth of ARCH’s biotechnology portfolio companies. He is a director of Accelerator, Allozyne, Variation Biotechnologies, Surface Logix, PhaseRx, Pulmatrix and Qwell Pharmaceuticals. He serves as director and chairman of VentiRx Pharmaceuticals, Spaltudaq and VLST. As a former director and chairman of Trubion Pharmaceuticals (TRBN), he led its acquisition by Emergent BioSolutions in early 2010.
Dr. Gillis was a founder and director of Corixa Corp. and served as the company’s chief executive officer from its inception and as its chairman from 1999 until its acquisition in 2005 by GlaxoSmithKline. Prior to Corixa, Dr. Gillis was a founder and director of Immunex Corp. From 1981 until his departure in 1994, he served as Immunex’s director of research and development, chief scientific officer, and as chief executive officer of Immunex’s R&D subsidiary. Dr. Gillis was interim chief executive officer of Immunex Corp. following its majority purchase by American Cyanamid Co. and remained a member of the board until 1997. Amgen, Inc. acquired Immunex in 2002.
Dr. Gillis is an immunologist by training with over 300 peer-reviewed publications in the areas of molecular and tumor immunology. He is credited as being a pioneer in the field of cytokines and cytokine receptors, directing the development of multiple marketed products including Leukine, (GM-CSF), Prokine (IL-2) and Enbrel (soluble TNF receptor-Fc fusion protein), as well as the regulatory approval of Bexxar (radiolabeled anti-CD20). Dr. Gillis received a B.A. from Williams College and a Ph.D. from Dartmouth College.
Kristina Burow is a Managing Director with ARCH Venture Partners and is focused on the creation and development of biotechnology, pharmaceutical and agbiotechnology companies. Since joining ARCH in 2002 Ms. Burow has played a significant role in the creation and development of a number of companies. Ms. Burow is a Director of Vividion Therapeutics, Lycera, BlackThorn Therapeutics, Sienna Biopharmaceuticals, Metacrine, Scholar Rock, Unity Biotechnology, AgBiome, AgTech Accelerator and Vir Biotechnology. She previously was a co-founder and Director of Receptos (RCPT – acquired by Celgene). Ms. Burow has participated in a number of other ARCH portfolio companies including Siluria Technologies, Kythera (KYTH – acquired by Allergan), Ikaria (acquired by Madison Dearborn) and was a co-founder and board member of Sapphire Energy. Prior to joining ARCH Ms. Burow was an Associate with the Novartis BioVenture Fund in San Diego. As an early employee at the Genomics Institute of the Novartis Research Foundation (GNF), she directed Chemistry Operations and was active in Business Development where she helped create numerous companies as spin-outs from GNF. Ms. Burow holds a M.B.A. from the University of Chicago, a M.A. in Chemistry from Columbia University and a B.S. in Chemistry from the University of California, Berkeley.
Pablo Cagnoni, MD
Dr. Cagnoni is the President and CEO of Tizona Therapeutics, an immunology company that is harnessing the power of the immune system to develop treatments for cancer and autoimmune diseases.
Over of the course of his career, Dr. Cagnoni has played a key role in the development, approval and/or commercialization of several life-changing medicines, including Afinitor®, Blincyto® Exjade®, Folotyn® Glivec®, Jakavi®, Kyprolis®, Signifor®, Tarceva®, Tasigna® and Zykadia® among them.
Most recently, he served as President of Onyx Pharmaceuticals where he had global strategic oversight and accountability of the business from early product development to commercialization of the Onyx portfolio. At the time of his departure, Onyx was on track to deliver yearly revenues in excess of $1B and had over 800 employees. Dr. Cagnoni joined Onyx in March 2013, as Executive Vice President, Global Research and Development and Technical Operations, and was named President in October 2013, when Onyx became an Amgen subsidiary. Previously, he was Senior Vice President and Global Head of Clinical Development at Novartis Oncology, where he was responsible for all clinical development, clinical operations, clinical pharmacology and correlative sciences activities for the oncology development pipeline. From 2007 to 2009, Dr. Cagnoni was Senior Vice President and Chief Medical Officer at Allos Therapeutics, and prior to that Chief Medical Officer of OSI Pharmaceuticals. Earlier in his career, he served as Assistant Professor of Medicine, University of Colorado Bone Marrow Transplant Program where he cared for patients undergoing stem cell transplants.
Dr. Cagnoni earned his medical degree from the University Buenos Aires School of Medicine, and he completed his fellowship in Hematology and Oncology at The Mount Sinai Medical Center, New York and a fellowship in Stem Cell Transplantation at the University of Colorado Health Sciences Center.
Dr. Cagnoni is also on the board of directors of Harpoon Therapeutics and CRISPR Therapeutics.
Mary Lincoln Campbell
Mary Lincoln Campbell, Managing Director and Founder of EDF Ventures, has been an active investor both in healthcare and technology companies. Currently, Mary is a board member or board observer for: Cerenis Therapeutics and Lycera (pharmaceuticals); IntelePeer (telecommunications); ValenTx (medical devices); Arxan (software); and Accio Energy (wind-energy).
Mary led several of the firm’s most successful transactions including HandyLab, a developer of molecular diagnostic assays and automation platforms, sold to Becton Dickinson & Company; Sircon, a provider of automation solutions for the insurance industry, sold to Vertafore, the nation’s number one insurance software provider; and Greenplum, a database clustering software for business intelligence and data warehousing, sold to EMC Corporation, the world’s leading provider of information infrastructure solutions.
She is active with The Stephen M. Ross School of Business at The University of Michigan and serves as an advisor to the Zell Lurie Institute for Entrepreneurial Studies, as well as its student-run venture activity, the Wolverine Venture Fund. She serves on the advisory board of The Charles F. Dolan School of Business at Fairfield University. Mary is past president of the Michigan Venture Capital Association, the State’s premier public policy advocate for the venture capital industry.
Mary received her MBA and BA in English from The University of Michigan and a Master of Special Education from Fairfield University.
Michael R. Hayden MB, ChB, PhD, FRCP (C), FRSC, C.M., O.B.C.
Dr. Michael Hayden is the President of Global R&D and Chief Scientific Officer at Teva. He has led research and development since 2012, leading to approval of approximately 35 new products by 2018.
In 2015 Teva R&D was recognized as one of the 10 most exciting innovators in Pharma by IDEA Pharma and in 2017 Teva R&D ranked top of the industry for CNS development and clinical trial success rate by Pharma Intelligence.
Dr. Hayden was recently named one of the 50 Canadians born in the 20th century who have changed the world. Dr. Hayden is the founder of three biotechnology companies: NeuroVir Therapeutics Inc., Xenon Pharmaceuticals Inc., and Aspreva Pharmaceuticals Corp.
Author of over 700 peer-reviewed publications and invited submissions, Michael has focused his research primarily on genetic diseases, including genetics of diabetes, lipoprotein disorders, Huntington disease, predictive and personalized medicine. Michael and his research group have identified 10 disease-causing genes which includes the identification of the major gene underlying high-density lipoprotein (HDL) in humans. Michael also identified the first mutations underlying Lipoprotein Lipase (LPL) Deficiency and developed gene therapy approaches to treat this condition, the first approved gene therapy in the western world. Michael is the most cited author in the world for ABCA1, and Huntington Disease.
He is also a Killam Professor at the University of British Columbia and the Director of the Translational Laboratory in Genetic Medicine at the National university of Singapore and Astar.
Michael is the recipient of numerous prestigious honours and awards. He was inducted into the Canadian Medical Hall of Fame in 2017. He was named one of PharmaVoice’s “100 of the Most Inspiring People” (2015); Awarded an Honorary Doctor of Science by the University of Gottingen (2014); the Luminary award by the Personalized Medicine World Conference (2014); July 2012 Diamond Jubilee Medal, on behalf of HRH Queen Elisabeth II, in recognition of his significant contributions and achievements, the Margolese National Brain Disorder Prize (2011), awarded to Canadians who have made outstanding contributions to the treatment, amelioration, or cure of brain diseases; the Killam Prize by the Canada Council of the Arts (2011), in recognition of his outstanding career achievements; and the Canada Gairdner Wightman award (2011), recognizing him as a physician-scientist who has demonstrated outstanding leadership in medicine and medical science. Michael has also been awarded the Order of Canada (2011), and the Order of British Columbia (2010). He was named Canada’s Health Researcher of the Year by CIHR (NIH of Canada) in 2008, and he received the Prix Galien in 2007, which recognizes the outstanding contribution of a researcher to Canadian pharmaceutical research.
Michael Hayden is committed to empowering others. In addition to mentoring over 100 graduate students and postdocs, he is also a TED mentor.
Robert Kamen, Ph.D.
Dr. Robert Kamen is a consultant to the biotech and pharmaceutical industry. Most recently, he was president of Abbott Bioresearch Center, Abbott Laboratories’ immunology drug discovery and biologics production unit in Worcester, Massachusetts, and a member of the Abbott Pharmaceuticals Executive Management Committee. During Dr. Kamen’s leadership at BASF/Abbott, the company established the technology platform for Humira™ (adalimumab), the first fully human antibody to achieve marketing approval in the U.S. (and Europe). Currently marketed for rheumatoid arthritis, psoriatic arthritis, Crohn’s disease and psoriasis, Humira was the most rapidly growing U.S. biological drug in 2007 and 2008. In 2005, Dr. Kamen co-founded BioAssets Development Corporation, a biotherapeutics company focusing on spinal diseases, where he serves as chairman. In addition, Dr. Kamen is a member of several other biopharmaceutical company boards.
Dr. Kamen has an undergraduate degree in biophysics from Amherst College and a Ph.D. in biochemistry and molecular biology from Harvard University.
Nina Kjellson joined Cannan’s healthcare team as General Partner in 2015 from InterWest Partners where she has been investing in healthcare start-ups since 2002. She focuses primarily on investments in biopharmaceuticals and digital health. Nina is co-founder and co-chair of ConsumerMed.org, a forum to address the convergence of health care and consumer innovation and serves as a mentor to Blueprint Health, a digital health incubator and Springboard Life Sciences, an accelerator for healthcare companies driven by women entrepreneurs. Investment themes include innovative therapeutics for serious and underserved conditions, IT-enabled transformation of healthcare delivery and patient/consumer engagement.
Current investments include Cidara (CDTX), Eiger Biopharmaceuticals, Lycera, Ocera (OCRX), Paratek (PRTK), and WellTok.
Previous investments include Labrys Biologics (acquired by Teva), Alt12 (acquired by Honest Company), Trius Therapeutics (TSRX; acquired by Cubist), CNS Therapeutics (acquired by Covidien), NovaCardia (acquired by Merck), and Aspreva (ASPV; acquired by Galenica) Prior to InterWest, Nina was an investment manager at Bay City Capital, a life sciences merchant bank, and a research associate at Oracle Partners, a health care-focused hedge fund. Nina began her career conducting health policy and survey research with the Kaiser Family Foundation.
Nina received a B.A. in human biology from Stanford University (1997).
She serves on the California Leadership Council for the Nature Conservancy and has been nominated to join the board of the California Family Health Council.
Paul Sekhri joined Lycera as President and CEO in February 2015. Prior to this he served as Senior Vice President, Integrated Care for Sanofi from April 2014 through January 2015. Previously, he served as Group Executive Vice President, Global Business Development and Chief Strategy Officer for Teva Pharmaceutical Industries, Lt. Prior to joining Teva he spent five years as Operating Partner and Head of the Biotechnology Operating Group at TPG Biotech, the life sciences venture capital arm of TPG Capital. From 2004-2009 Mr. Sekhri was Founder, President, and Chief Executive Officer of Cerimon Pharmaceuticals, Inc. Prior to founding Cerimon, Mr. Sekhri was President and Chief Business Officer of ARIAD Pharmaceuticals, Inc.
Previously, Mr. Sekhri spent four years at Novartis, as Senior Vice President, and Head of Global Search and Evaluation, Business Development and Licensing for Novartis Pharma AG. Mr. Sekhri also developed the Disease Area Strategy for Novartis, identifying those specific therapeutic areas upon which the company would focus. His first role at Novartis was as Global Head, Early Commercial Development – a department he established to ensure the differential competitive advantage of Novartis’ pipeline.
Mr. Sekhri completed graduate work in Neuroscience at the University of Maryland School of Medicine, where he also received his BS in Zoology.
Mr. Sekhri has been a Director on sixteen private and public company Boards, and is currently a member of the Board of Directors of Veeva System, Pharming N.V., Enumeral Biomedical, and was a recent board observer at IMS Health.
Additionally, he is on the Board of Directors of the non-profit Cancer Research Institute, the BioExec Institute, Inc., the Industry Advisory Board of the Michael J. Fox Foundation, the TB Alliance, the Tectonic Theatre Project, and was recently elected to the Board of Directors of Young Concert Artists, Inc. Mr. Sekhri also served as a Member of the Board of Trustees of Carnegie Hall from 2010-2012, where he is now an active member of their Patrons Council.
Nicholas J. Simon, MBA
Nicholas Simon has served as managing director of Clarus Ventures since the firm’s inception in 2005. Previously, Mr. Simon was general partner at MPM Capital. He has over 20 years of operating and investment experience in the biopharmaceutical industry, including at Genentech from 1989 to 2000, where he was vice president of business and corporate development.
Mr. Simon also represents Clarus Ventures on the Board of Directors of Gritstone Oncology, Nuvelution Pharma, Inc. and Sientra, where he serves as Lead Director. In addition, he is a member of the Foundation Board at the Gladstone Institute, a private not-for-profit research institute affiliated with the University of California, San Francisco.
Mr. Simon received his BS degree in microbiology from the University of Maryland and MBA from Loyola University.